Recent publications have shown that HCPs shorten shelf-life of monoclonal antibodies (mAbs), aggregate or proteolytically cleave mAbs inside the bioreactor and interfere with the binding of mAbs during purification leading to lower purification yield. However, it is a major challenge to remove these HCPs as they are cell-derived impurities. We have developed a novel perfusion filter that can remove dead cells from the bioreactor leading to lower HCP impurities in the cell culture. Our perfusion filter uses the principle of high density inertial microfluidics and is based on a new scientific discovery in our group. We have also developed a numerical model to understand our discovery so that we can optimize the design for higher throughput. This novel perfusion filter is clog-free, can work up to a cell concentration of 108 cells/ml and has the ability to remove dead cells from the bioreactor. This technology has been described as disruptive by big biopharmaceutical companies and we will be sharing more about this technology in this presentation.